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Renal transplantation and infection-focus on 
CMV 
V.C. Emery. Royal Free and Uniuersity College Medical School, London, 
UK 
CMV is a continuing cause of morbidity in the renal transplant 
recipient. As more high-risk transplantation is performed due to lack 
of suitably matched organs, the incidence of .CMV infection is 
increasing. My talk will focus on the insight that CMV load measures 
can provide in understanding the pathogenesis of CMV disease and 
the interrelationship between viral load in the blood and urine and 
established risk factors for CMV disease such as donodrecipient 
CMV serostatus, augmented immunosuppression, etc. A series of 
investigations in my laboratory has shown, using quantitative PCR 
methods, that CMV load is the most important parameter in CMV 
pathogenesis and accounts for the previous risk factors. The utility of 
these data in the context of antiviral intervention will then be 
discussed-how effective therapy needs to be to suppress replication 
and impact on disease, and the benefitddrawbacks of pre-emptive 
versus prophylactic regimens. I will conclude by discussing recent 
data implicating HHV-7 as a cofactor for CMV disease in renal 
transplant recipients and the possibility that controlled clinical trials 
aimed at inhibiting CMV replication may produce beneficial effects 
through inhibition of other beta-herpesviruses. 
ls247] Infections in ICU patients: focus on resistant 
bacteria 
J. Chastre. Rlanimation MtYicale, Hdpital Bichat, Paris, Frarice 
The importance of multiresistant microorganisms as a cause of 
nosocomial infection in ICU patients has been documented in many 
studies. By now, many Pseudumonar aeruginusa and .4cinetubacter 
baumannii strains are class I cephalosporinase producers and are 
resistant to piperacillin, aztreonam and ceftazidime. Klebsiella 
pneumoniae strains are also increasingly recognized as producers of 
transferable extended-spectrum beta-lactamases which confer resist- 
ance to third-generation cephalosporins. Other multiresistant aerobic 
Gram-negative bacilli include Xanthomonas (Stenotrophomunas) malto- 
philia and akcalkenes. Unfortunately, methicillin-resistant Staphylococcus 
aureus is also more and more frequently implicated as a causative 
pathogen in very sick patients who require ICU care for a long period 
of time. Therefore, the microbiological trends in nosocomial 
infection are evolving towards more resistant and more difficult-to- 
treat pathogens. A large body of evidence strongly supports the 
observation that the indiscriminate use of antimicrobial agents in 
ICU patients has immediate but also long-term consequences, 
contributing to the emergence of multiresistant pathogens and 
increasing the risk of serious superinfections. Virtually all reports 
emphasize that better antibiotic control programs In order to limit 
bacterial resistance are urgently needed in ICUs and that patients 
without true infection should not receive antimicrobial treatment. 
Therefore, it should be made clear to physicians confronted with 
ICU patients clinically suspected of having developed nosocomial 
infection that treating all these patients with new antimicrobial agents 
may lead to overtreatment in a large number of cases and, thus, to 
the rapid emergence of multiresistant pathogens not only in the 
treated patients but also in other patients hospitalized in the same 
m i  t . 
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Is252J Outcome modeling in infectious diseases 
A. Brandt. Irrstitutefor Medical Infurmatics and Biustafistics, Riehen, 
Switzerland 
Medical economic evaluations have been performed for many 
pharmaceutical substances and immunization programs. Study results 
have helped to improve health policy decisions regarding preventive 
immunization and acute treatment. Disease models are used to 
estimate the medical outcomes and cost consequences of alternative 
intervention strategies, not just pharmaceutical treatments. Studies 
indicate that primary prevention is often more efficient in high-risk 
rather than low-risk populations and that secondary prevention tends 
to be more efficient than primary prevention. 
The evaluation of alternative antimicrobial treatments requires 
answers to a sequence of questions: Who needs treatment? How is 
the target population defined? What are the best treatments, doses, 
routes of administration, and duration of treatment? How can the 
expected long-term medical outcomes be estimated for a given target 
population, particularly in the face of only short-term evidence? 
What are the expected cost consequences of alternative treatments? 
Disease models attempt to represent disease processes, based on a 
synthesis of available medical data. They simulate the development of 
diseases for different patient populations under different management 
strategies: extrapolate short-term data and surrogate endpoints to 
long-term clinical outcomes; extrapolate from trial data to popu- 
lation (efficacy to effectiveness) in clinical practice; what-if analyses 
of different assumptions. Additionally, disease models allow us to 
determine the most important efficiency parameter as well as cost 
parameter by sensitivity analysis as well as to direct scarce resources 
to efficient treatments. 
Infections by non-tuberculous mycobacteria 
Infections by non-tuberculous mycobacteria 
J. Falkinham, L’irginia State University, Fralin Biotechnulugy Center, 
Blacksburg, 1.2, USA 
Non-tuberculous mycobacteria are opportunistic, intracellular 
pathogens whose source is environmental. Infection is associated with 
predisposing conditions: lung disease, alteration in chest architecture, 
or immune deficiency. Lung, skin, lymph node, gastrointestinal, 
disseminated and nosocomial infections have been reported. 
Examples of non-tuberculous mycobacteria causing pulmonary 
infections include Mycubacterium kansasii, M .  avium, M .  intracellulare, 
M. malmoenre and M .  xenopi. Though the epidemiologies of the 
infections differ, hf. marinum, M. haemophilnm and M.  ulcerans have 
all been implicated in skin infections. 111. auium is responsible cervical 
lymphadenitis in children. M. paratuberculosis causes diarrheal disease 
Uohne’s) in cattle and may be responsible for Crohn’s disease in 
humans. Although the majority of disseminated infections in AIDS 
patients are caused by M.  auium, other mycobacterial species, 
including M.  kansasii, Af. malmoense and newly identified species (e.g. 
M. genavense), are responsibie for infection as well. 
One source of non-tuberculous mycobacterial Infection is water. 
iLf. auiurn isolates from water have DNA fingerprints matching those 
of isolates from either human AIDS patients or SIV-infected monkeys 
who drank the water. Outbreaks of M. xenupi and M. ulerans have 
been associated, in time, with recovery from hot water systems or the 
